On July 13, the Phase III clinical trial of recombinant herpes zoster vaccine (CHO cell) of Chengdu MAXVAX Biotechnology Co., Ltd (MAXVAX) completed the enrollment of the first subject in Liangyuan District, Shangqiu City, Henan Province, marking the successful start of the Phase III clinical trial of the recombinant herpes zoster vaccine of MAXVAX. The vaccine product adopts recombinant protein technology route and carries independently developed new adjuvant system MA105, which is the first innovative vaccine with composite adjuvant system with independent intellectual property rights to enter phase Ⅲ clinical trial in China. The results of Phase I and Phase II clinical trials show that it has good safety, tolerability and immunogenicity. Phase III clinical trials will further verify the safety, immunogenicity and protective efficacy of the vaccine in a large sample of people, providing key data for the product's marketing application.

About Herpes Zoster Vaccine

Herpes zoster is a viral infection caused by reactivation of varicella zoster virus (the virus that causes chickenpox) and manifests as a painful rash, known as ''snakebite'', most commonly seen in people over 50 years of age, and herpes zoster vaccination is the most effective way to prevent herpes zoster and postherpetic neuralgia. and postherpetic neuralgia.

Compared with the live attenuated herpes zoster vaccine, which is no longer used in the United States, the recombinant herpes zoster vaccine with a new adjuvant system can activate stronger cellular immunity, improve the vaccine's immune efficacy in the elderly and people with impaired immune systems, and give better and longer-lasting protection to the vaccinated population.

The recombinant herpes zoster vaccine (CHO cell) developed by MAXVAX is the first domestic herpes zoster vaccine with a new adjuvant system with independent intellectual property rights, and has entered Phase III clinical stage. By developing adjuvant molecules and adjuvant systems with independent intellectual property rights, MAXVAX Bio is expected to be among the first tier of the global biopharmaceutical industry, providing safer and more effective prevention options for patients at home and abroad.

https://mp.weixin.qq.com/s?__biz=MzU1OTExMzAwNA==&mid=2247488091&idx=1&sn=ef52427ef6e20bb634511684342a0abe&chksm=fc1d6418cb6aed0e4bc7f2955be8b0ecdac5ae1ae90d5a15ed39559237ce73f3feb5ad04fc03&mpshare=1&scene=1&srcid=0715Qn8O2h8YTLUreHfdyDjI&sharer_shareinfo=0237ae76fa54c7ec8d9a47bebaab9618&sharer_shareinfo_first=0237ae76fa54c7ec8d9a47bebaab9618#rd